Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasisMarch 11, 2022Psoriatic ArthritisPsoriasis
Proactive infliximab monitoring found best for sustaining control of inflammatory diseasesJanuary 10, 2022Psoriatic ArthritisPsoriasis
Serious infection hospitalizations have declined in patients with PsANovember 19, 2021Psoriatic Arthritis
Better COVID-19 outcomes confirmed in TNF inhibitor usersOctober 22, 2021Psoriatic ArthritisPsoriasis
Few JAK inhibitor users have diminished immune response to COVID-19 vaccinesOctober 18, 2021Psoriatic Arthritis
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findingsOctober 13, 2021Psoriatic ArthritisPsoriasis
European agency recommends two new adalimumab biosimilarsSeptember 20, 2021Psoriatic ArthritisPsoriasis
Medicare patients’ cost burden for specialty psoriasis, PsA drugs remains highSeptember 15, 2021PsoriasisPsoriatic Arthritis
Cannabidiol found no better than placebo for hand arthritis painSeptember 15, 2021Psoriatic Arthritis
Psoriatic arthritis health care costs continue to rise over timeAugust 24, 2021Psoriatic ArthritisPsoriasis
Physicians question the future of TNF inhibitors for psoriasis, PsAAugust 6, 2021Psoriatic ArthritisPsoriasis
Researchers stress importance of second COVID-19 vaccine dose for infliximab usersApril 6, 2021Psoriatic ArthritisPsoriasis
